Oct 25, 2016

Abiomed's Impella Technology Showcased at TCT 2016 With More Than 25 Presentations During Scientific Sessions

Abiomed is Committed to Improving Outcomes in Protected PCI and Cardiogenic Shock

DANVERS, Mass., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Abiomed Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, announces that there are more than 25 presentations potentially featuring the Impella® line of heart pumps, scheduled during the scientific sessions at the Cardiovascular Research Foundation's (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) 2016 scientific meeting, being held October 29 — November 2, at the Walter E. Washington Convention Center in Washington, DC.

Abiomed is committed to improving outcomes in Protected PCI and cardiogenic shock through technology and innovation, excellence in education, clinical research, and appropriate and standardized use. The following initiatives are planned for TCT:

The schedule for Protected PCI and cardiogenic shock-related TCT symposia is included below.  Additional Impella-related presentations and poster sessions are anticipated at TCT.  

New FDA Indications for the Use of Percutaneous Hemodynamic Support: Improving Outcomes in Protected PCI and CGS Presentation Theater Program (Sponsored by the Cardiovascular Research Foundation)
Walter E. Washington Convention Center — Presentation Theater 3

11:30 AM — 12:30 PM
Navin K. Kapur, MD
William L. Lombardi, MD
James M. McCabe, MD

TCT Breakfast Session: Management of Complex PCI Patients: Award Winning Case Presentations Fellows - Breakfast Symposium
Walter E. Washington Convention Center — Room 143A, Street Level

6:30 — 8:00 AM
Michael P. Flaherty, MD
Perwaiz M. Meraj, MD
George W. Vetrovec, MD
Sukhdeep Singh Basra, MD
Nileshkumar Patel, MD
Nishtha Sareen, MD

TCT Symposium: The Interventional Toolbox for Complex Higher-Risk (and Indicated) Patients (CHIP) Co-Sponsored Evening Program (Sponsored by the Cardiovascular Research Foundation)
Marriott Marquis Washington, D.C. — Marquis Ballroom (Salon 5)

6:00 — 8:00 PM
Jeffrey W. Moses, MD
Gregg W. Stone, MD
Ajay J. Kirtane, MD
Emmanouil S. Brilakis, MD
Susheel Kodali, MD
Manish A. Parikh, MD
Simon J. Walsh, MD

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart.  For additional information please visit: www.abiomed.com.

This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and quarterly report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

For further information please contact: 

Ingrid Goldberg 
Director, Investor Relations